Early clinical experience with the novel proteasome inhibitor PS-519

British Journal of Clinical Pharmacology

Volumn 54, Issue 3, 2002, Pages 269-276

  Shah, I M ^a   Lees, K R ^a   Pien, C P ^b   Elliott, P J ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Neuroprotection; Nuclear factor kappa B (NF B); Proteasome inhibitors; Safety and tolerability

Indexed keywords

1 (1 HYDROXY 2 METHYLPROPYL) 4 PROPYL 6 OXA 2 AZABICYCLO[3.2.1.]HEPTANE 3,7 DIONE; LACTACYSTIN BETA LACTONE; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME INHIBITION; FLU LIKE SYNDROME; HEADACHE; HUMAN; LABORATORY TEST; MALE; NEUROPROTECTION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; TASTE DISORDER;

ACETYLCYSTEINE; BILIRUBIN; BLOOD PRESSURE; CYSTEINE ENDOPEPTIDASES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; LEUKOCYTE COUNT; MALE; MULTIENZYME COMPLEXES; NEUTROPHILS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 0036379624     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01638.x     Document Type: Article

References (16)

1. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway. is required for processing the NF-B1 precursor protein and the activation of NF-κB. Cell 1994; 78: 773-785.
2. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The. proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995; 2: 493-506.
3. Stephenson D, Yin T, Smalstig EB, et al. Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia. J Cereb Blood Flow Metab 2000; 20: 592-603.
4. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNF-nduced cell, death. Science 1996; 274: 782-784.
5. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Ann Rev Immunol 1994; 12: 141-179.
6. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann Rev Immunol 1996; 14: 649-683.
7. Karin M. How NF-kappaB is activated. the role of the IkappaB kinase (IKK) complex. Oncogene 1999; 18: 6867-6874.
8. Soucy F, Plamondon L, Behnke M, Roush W. Synthesis of clasto-lactacystin β-lactone and analogs thereof. J Am Chem Soc 1999; 121: 9967-9976.
9. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC, Clemens JA. Proteasome inhibitor PS-519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischaemia. Editorial comment. Stroke 2000; 31: 1686-1693.
10. Griscavage JM, Wilk S, Ignarro LJ. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. Proc Natl Acad Sci U S A 1996; 93: 3308-3312.
11. Campbell B, Adams J, Shin YK, Lefer AM. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 1999; 31: 467-476.
12. Zhang L, Zhang ZG, Rui Lan Zhang, et al. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001; 32: 2926-2931.
13. Hickenbottom SL, Grotta JC, Strong R, Denner LA, Aronowski J. Nuclear factor-kappaB and cell death after experimental intracerebral hemorrhage in rats. Stroke 1999; 30: 2472-2477.
14. Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 2000; 14: 205-211.
15. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J. Proteasome inhibition. A novel mechanism to combat asthma. J Allergy Clin Immunol 1999; 104 (2 Part 1): 294-300.
16. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46: 673-683.